What Is Larazotide Studied For? Research Areas, Per the Literature

This page describes what published studies have examined, organised by research area, with the study type and model stated alongside each citation.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms or treatment decisions.

What Larazotide Is, in the Literature

Larazotide acetate, also written AT-1001, is a short synthetic peptide described in the literature as a zonulin pathway inhibitor and tight junction regulator. A narrative review of the compound described it as acting at the intestinal epithelial tight junction rather than systemically, and framed tight junction regulation as the mechanistic rationale for studying it in celiac disease (PMID 26770266). A separate review catalogued the peptide under the label AT-1001 and surveyed proposals for its study across a range of acute and chronic inflammatory conditions (PMID 33397225).

Because the molecule is positioned as a barrier modulator rather than an immunosuppressant or enzyme, research areas cluster around conditions in which increased intestinal permeability has been proposed as a contributing factor. The strength of evidence differs sharply between those areas, and that difference is stated plainly below.

Research Area 1: Celiac Disease

Celiac disease is the area with the most human data. A systematic review and meta-analysis of randomised controlled trials pooled trials of larazotide acetate in celiac disease and reported on symptom and permeability endpoints across those randomised human studies (PMID 34339872). That meta-analysis is the single most relevant reference for anyone asking what the compound has actually been tested for in people.

Review articles place that trial work in context. A 2016 review of tight junction regulation in celiac disease focused specifically on larazotide acetate and described the rationale for targeting paracellular permeability in patients who remain symptomatic despite gluten restriction (PMID 26770266). A 2020 review of therapeutic options beyond the gluten-free diet listed larazotide among investigational approaches being evaluated for coeliac disease alongside enzyme and immune-directed candidates (PMID 31831308). A 2025 update on current treatments for celiac patients again reviewed the landscape of non-dietary candidates under investigation (PMID 41010485), and a review in Gut on the coeliac intestinal barrier discussed mechanisms of barrier disruption and strategies aimed at restoration (PMID 40579122).

What those reviews collectively describe is an investigational compound with completed randomised trials rather than an approved therapy; the meta-analysis of randomised controlled trials remains the primary human evidence base (PMID 34339872).

Formulation Research in Celiac Disease

Because the peptide is studied as a locally acting agent, delivery to the correct intestinal segment has itself been a research question. An in vivo study in a porcine model assessed a delayed release formulation of larazotide acetate indicated for celiac disease, examining release behaviour in the animal gastrointestinal tract (PMID 33844694). That work was animal only and addressed formulation performance rather than clinical outcomes in patients.

Research Area 2: Intestinal Barrier Injury and Repair

Outside celiac disease, the largest preclinical theme is repair of damaged intestinal epithelium. An animal study using ischemia-injured porcine jejunum reported that larazotide acetate induced recovery of the injured tissue through repair of tight junctions (PMID 33886649). The model was ischemic intestinal injury in pigs, not a human disease population, and the endpoints were barrier recovery measures rather than patient-reported outcomes.

This line of work is best read as mechanistic support for the barrier hypothesis. It does not establish that the same recovery occurs in humans with intestinal ischemia, and the published porcine study did not test that question (PMID 33886649).

Research Area 3: Colitis and Inflammatory Bowel Models

Colitis has been approached mainly through drug delivery chemistry. A 2025 study described an antibacterial hyaluronic acid hydrogel providing sustained release of larazotide and evaluated it as a colitis treatment in a laboratory and animal setting (PMID 40915363). The emphasis of that work was on the delivery system as much as the peptide, and it did not involve a human patient population.

Evidence for larazotide in inflammatory bowel disease in people is absent from the verified literature set on this page. The only colitis-relevant citation here is preclinical (PMID 40915363).

Research Area 4: Arthritis and Autoimmunity

A 2020 study in Nature Communications investigated targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis, linking gut barrier integrity to arthritis development in experimental work (PMID 32332732). This was mechanistic and preclinical in nature rather than a clinical trial in patients with rheumatoid arthritis.

The broader review of AT-1001 across inflammatory conditions also discussed the premise that barrier restoration might be relevant to several autoimmune processes, while treating those applications as proposals for further study rather than established uses (PMID 33397225).

Research Area 5: Vascular Tight Junctions

One line of research moved outside the gut entirely. A 2023 study in the European Heart Journal examined endothelial tight junctions as a target to predict and protect against thoracic aortic aneurysm and dissection, extending tight junction pharmacology into vascular biology (PMID 36638776). This was laboratory and animal work on vascular barrier biology, not a trial in patients with aortic disease.

Research Area 6: Antiviral Chemistry

During the COVID-19 period, chemists explored the scaffold rather than the marketed candidate. A 2021 study synthesised peptide derivatives of the zonulin inhibitor larazotide (AT1001) as potential anti SARS-CoV-2 agents, combining molecular modelling, synthesis and bioactivity evaluation in vitro (PMID 34502335). The work concerned derivative molecules assessed in laboratory assays, and no human antiviral data were reported in that study (PMID 34502335).

Evidence Map by Research Area

Safety and Tolerability: What Studies Report

Tolerability information in the verified literature comes mainly from pooled clinical work. The systematic review and meta-analysis of randomised controlled trials in celiac disease assessed larazotide acetate across trials and reported on outcomes including tolerability within those randomised studies (PMID 34339872). Review articles covering investigational celiac therapies likewise discussed the candidate within a safety and development framework rather than reporting new adverse event data (PMID 31831308, PMID 41010485).

Preclinical studies in pigs examined formulation and tissue level endpoints rather than long term human safety, so they cannot speak to adverse events in people (PMID 33844694, PMID 33886649). No dosing figures are stated on this page because the verified citation set here is summarised at the level of study design and research area.

Where the Evidence Is Weak or Missing

• Non-celiac gut complaints: the verified set contains no human trial in people without celiac disease; barrier repair data come from an animal ischemia model (PMID 33886649).
• Inflammatory bowel disease: represented only by a preclinical hydrogel delivery study (PMID 40915363).
• Autoimmune disease broadly: arthritis work was experimental, and the review framing of AT-1001 across inflammatory diseases described potential rather than demonstrated clinical benefit (PMID 32332732, PMID 33397225).
• Cardiovascular and antiviral uses: limited to preclinical and laboratory work on tight junction biology and synthesised derivatives (PMID 36638776, PMID 34502335).

How to Read This Body of Work

Three distinctions help when interpreting claims about larazotide. First, study type: a randomised trial in patients carries different weight from a pig model, and the celiac meta-analysis is the only pooled human evidence cited here (PMID 34339872). Second, endpoint: permeability markers and tight junction measures are mechanistic readouts, as used in the porcine jejunum study (PMID 33886649), and are not the same as symptom resolution. Third, molecule identity: the antiviral paper tested derivatives of the peptide rather than larazotide itself (PMID 34502335).

Reviews published in 2025 and 2026 continued to describe celiac disease management as centred on gluten restriction, with barrier directed and other candidates still under investigation (PMID 41010485, PMID 40579122).

Summary

Published research on larazotide spans celiac disease trials pooled in a meta-analysis (PMID 34339872), animal barrier repair work (PMID 33886649), preclinical colitis delivery chemistry (PMID 40915363), experimental arthritis prevention (PMID 32332732), vascular tight junction biology (PMID 36638776) and in vitro derivative chemistry (PMID 34502335). This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician with any medical question.

References

• Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials (Clinics and Research in Hepatology and Gastroenterology, 2022)
• The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate (Therapeutic Advances in Gastroenterology, 2016)
• Therapeutic options for coeliac disease: What else beyond gluten-free diet? (Digestive and Liver Disease, 2020)
• Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments (Nutrients, 2025)
• Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration (Gut, 2026)
• In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model (PLoS One, 2021)
• Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions (PLoS One, 2021)
• Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment (Journal of Controlled Release, 2025)
• Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis (Nature Communications, 2020)
• Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection (European Heart Journal, 2023)
• Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation (International Journal of Molecular Sciences, 2021)
• The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases (Current Medicinal Chemistry, 2021)